SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
---|---|---|---|---|---|---|---|---|---|
24-Apr-24 4:17 PM View: | Russotti Gregory See Remarks | Century Therapeutics, Inc. (IPSC) | 22-Apr-24 | Sale (Planned) | 5,000 | $3.10 | $15,489.50 | (1%) 395.09K to 390.09K | |
11-Mar-24 7:34 PM View: | Levitsky Hyam President of R&D | Century Therapeutics, Inc. (IPSC) | 07-Mar-24 | Grant | 24,000 | -- | -- | 4% 536.54K to 560.54K | |
18-Mar-24 5:48 PM View: | Pfeiffenberger Brent President and CEO Director | Century Therapeutics, Inc. (IPSC) | 07-Mar-24 | Grant | 17,425 | -- | -- | 1% 1.45M to 1.47M | |
08-Mar-24 6:29 PM View: | Farid Adrienne Chief Operations Officer | Century Therapeutics, Inc. (IPSC) | 07-Mar-24 | Planned Option Sale | 22,831 | $5.14 | $117,342.00 | (17%) 136.98K to 114.15K | |
11-Mar-24 7:35 PM View: | Farid Adrienne Chief Operations Officer | Century Therapeutics, Inc. (IPSC) | 07-Mar-24 | Grant | 24,000 | -- | -- | 21% 114.15K to 138.15K | |
11-Mar-24 7:36 PM View: | Russotti Gregory See Remarks | Century Therapeutics, Inc. (IPSC) | 07-Mar-24 | Grant | 24,000 | -- | -- | 6% 371.09K to 395.09K | |
08-Mar-24 6:29 PM View: | Farid Adrienne Chief Operations Officer | Century Therapeutics, Inc. (IPSC) | 07-Mar-24 | Option Exercise | 22,831 | $1.03 | $23,515.90 | 20% 114.15K to 136.98K | |
11-Mar-24 7:38 PM View: | Carr Douglas SVP Finance & Operations | Century Therapeutics, Inc. (IPSC) | 07-Mar-24 | Grant | 14,000 | -- | -- | 5% 303.58K to 317.58K | |
08-Mar-24 6:29 PM View: | Farid Adrienne Chief Operations Officer | Century Therapeutics, Inc. (IPSC) | 06-Mar-24 | Option Exercise | 30,684 | $1.03 | $31,604.50 | 27% 114.15K to 144.83K | |
08-Mar-24 6:29 PM View: | Farid Adrienne Chief Operations Officer | Century Therapeutics, Inc. (IPSC) | 06-Mar-24 | Planned Option Sale | 30,684 | $4.96 | $152,340.00 | (21%) 144.83K to 114.15K | |
21-Feb-24 4:10 PM View: | Farid Adrienne Chief Operations Officer | Century Therapeutics, Inc. (IPSC) | 16-Feb-24 | Planned Option Sale | 485 | $4.86 | $2,358.26 | (< 1%) 114.63K to 114.15K | |
21-Feb-24 4:10 PM View: | Farid Adrienne Chief Operations Officer | Century Therapeutics, Inc. (IPSC) | 16-Feb-24 | Option Exercise | 485 | $1.03 | $499.55 | < 1% 114.15K to 114.63K | |
07-Feb-24 5:21 PM View: | Farid Adrienne Chief Operations Officer | Century Therapeutics, Inc. (IPSC) | 06-Feb-24 | Sale | 1,784 | $4.49 | $8,004.81 | (2%) 115.93K to 114.15K | |
07-Feb-24 5:21 PM View: | Carr Douglas SVP Finance & Operations | Century Therapeutics, Inc. (IPSC) | 06-Feb-24 | Sale | 557 | $4.49 | $2,499.26 | (< 1%) 304.14K to 303.58K | |
07-Feb-24 5:21 PM View: | Carr Douglas SVP Finance & Operations | Century Therapeutics, Inc. (IPSC) | 05-Feb-24 | Sale | 643 | $3.84 | $2,469.76 | (< 1%) 304.78K to 304.14K | |
07-Feb-24 5:21 PM View: | Farid Adrienne Chief Operations Officer | Century Therapeutics, Inc. (IPSC) | 05-Feb-24 | Sale | 2,035 | $3.84 | $7,816.44 | (2%) 117.97K to 115.93K | |
06-Dec-23 4:07 PM View: | Pfeiffenberger Brent President and CEO Director | Century Therapeutics, Inc. (IPSC) | 04-Dec-23 | Grant | 1,453,280 | -- | -- | 100% 0 to 1.45M | |
03-Nov-23 4:04 PM View: | Carr Douglas SVP Finance & Operations | Century Therapeutics, Inc. (IPSC) | 01-Nov-23 | Payment of Exercise | 16,611 | $1.49 | $24,750.40 | (5%) 321.39K to 304.78K | |
03-Nov-23 4:04 PM View: | Diem Michael Craig Chief Financial Officer | Century Therapeutics, Inc. (IPSC) | 01-Nov-23 | Payment of Exercise | 20,763 | $1.49 | $30,936.90 | (8%) 274.3K to 253.53K | |
17-May-23 4:33 PM View: | Carr Douglas SVP Finance & Operations | Century Therapeutics, Inc. (IPSC) | 15-May-23 | Grant | 120,846 | -- | -- | 60% 200.54K to 321.39K | |
17-May-23 4:32 PM View: | Diem Michael Craig Chief Financial Officer | Century Therapeutics, Inc. (IPSC) | 15-May-23 | Grant | 151,058 | -- | -- | 123% 123.24K to 274.3K | |
05-Apr-23 4:27 PM View: | Borges Luis Chief Scientific Officer | Century Therapeutics, Inc. (IPSC) | 03-Apr-23 | Option Exercise | 7,452 | $1.03 | $7,675.56 | 3% 249.08K to 256.54K | |
23-Mar-23 7:31 PM View: | Borges Luis Chief Scientific Officer | Century Therapeutics, Inc. (IPSC) | 23-Mar-23 | Option Exercise | 220,930 | $1.03 | $227,558.00 | 505% 43.75K to 264.68K | |
23-Mar-23 7:31 PM View: | Borges Luis Chief Scientific Officer | Century Therapeutics, Inc. (IPSC) | 23-Mar-23 | Option Sale | 15,597 | $3.55 | $55,369.30 | (6%) 264.68K to 249.08K | |
23-Mar-23 7:31 PM View: | Borges Luis Chief Scientific Officer | Century Therapeutics, Inc. (IPSC) | 22-Mar-23 | Option Exercise | 65,698 | $1.03 | $67,668.90 | 150% 43.75K to 109.45K | |
23-Mar-23 7:31 PM View: | Borges Luis Chief Scientific Officer | Century Therapeutics, Inc. (IPSC) | 22-Mar-23 | Option Sale | 65,698 | $3.72 | $244,640.00 | (60%) 109.45K to 43.75K | |
23-Mar-23 7:31 PM View: | Borges Luis Chief Scientific Officer | Century Therapeutics, Inc. (IPSC) | 21-Mar-23 | Option Sale | 63,616 | $3.77 | $239,870.00 | (59%) 107.37K to 43.75K | |
23-Mar-23 7:31 PM View: | Borges Luis Chief Scientific Officer | Century Therapeutics, Inc. (IPSC) | 21-Mar-23 | Option Exercise | 63,616 | $1.03 | $65,524.50 | 145% 43.75K to 107.37K | |
06-Feb-23 6:52 PM View: | Carr Douglas VP Finance & Operations | Century Therapeutics, Inc. (IPSC) | 02-Feb-23 | Grant | 15,000 | -- | -- | 8% 185.54K to 200.54K | |
06-Feb-23 6:49 PM View: | Farid Adrienne Chief Operations Officer | Century Therapeutics, Inc. (IPSC) | 02-Feb-23 | Grant | 43,750 | -- | -- | 59% 74.22K to 117.97K | |
06-Feb-23 6:50 PM View: | Borges Luis Chief Scientific Officer | Century Therapeutics, Inc. (IPSC) | 02-Feb-23 | Grant | 43,750 | -- | -- | 100% 0 to 43.75K | |
06-Feb-23 6:49 PM View: | Diem Michael Craig Chief Business Officer | Century Therapeutics, Inc. (IPSC) | 02-Feb-23 | Grant | 43,750 | -- | -- | 55% 79.49K to 123.24K | |
11-Aug-22 4:55 PM View: | Versant Venture Capital Vi,... 10% Owner | Century Therapeutics, Inc. (IPSC) | 09-Aug-22 | Disposition (other) | 364,800 | -- | -- | (3%) 13.08M to 12.72M | |
11-Aug-22 4:55 PM View: | Versant Venture Capital Vi,... 10% Owner | Century Therapeutics, Inc. (IPSC) | 09-Aug-22 | Sale (Planned) | 550,000 | $13.03 | $7,166,610.00 | (4%) 12.72M to 12.17M | |
02-Feb-22 4:31 PM View: | Versant Venture Capital Vi,... 10% Owner | Century Therapeutics, Inc. (IPSC) | 31-Jan-22 | Disposition (other) | 178,996 | -- | -- | (1%) 13.26M to 13.08M | |
28-Dec-21 4:46 PM View: | Versant Venture Capital Vi,... 10% Owner | Century Therapeutics, Inc. (IPSC) | 23-Dec-21 | Disposition (other) | 371,004 | -- | -- | (3%) 13.63M to 13.26M | |
23-Jun-21 4:30 PM View: | Versant Venture Capital Vi,... 10% Owner | Century Therapeutics, Inc. (IPSC) | 22-Jun-21 | Conversion | 614,095 | -- | -- | 5% 12.92M to 13.53M | |
23-Jun-21 4:30 PM View: | Versant Venture Capital Vi,... 10% Owner | Century Therapeutics, Inc. (IPSC) | 22-Jun-21 | Private Purchase | 100,000 | $20.00 | $2,000,000.00 | < 1% 13.53M to 13.63M | |
22-Jun-21 4:31 PM View: | Casdin Eli Director | Century Therapeutics, Inc. (IPSC) | 22-Jun-21 | Conversion | 2,456,380 | -- | -- | 100% 2.46M to 4.91M | |
23-Jun-21 4:41 PM View: | Bayer Aktiengesellschaft 10% Owner | Century Therapeutics, Inc. (IPSC) | 22-Jun-21 | Private Purchase | 750,000 | $20.00 | $15,000,000.00 | 6% 11.93M to 12.68M | |
22-Jun-21 4:31 PM View: | Casdin Eli Director | Century Therapeutics, Inc. (IPSC) | 22-Jun-21 | Private Purchase Duplicate | 750,000 | $20.00 | $15,000,000.00 | 15% 4.91M to 5.66M | |
23-Jun-21 5:00 PM View: | Fujifilm Cellular Dynamics,... 10% Owner | Century Therapeutics, Inc. (IPSC) | 22-Jun-21 | Conversion | 3,974,400 | -- | -- | 133% 2.98M to 6.96M | |
23-Jun-21 4:30 PM View: | Versant Venture Capital Vi,... 10% Owner | Century Therapeutics, Inc. (IPSC) | 22-Jun-21 | Conversion | 9,936,010 | -- | -- | 333% 2.98M to 12.92M | |
23-Jun-21 4:41 PM View: | Bayer Aktiengesellschaft 10% Owner | Century Therapeutics, Inc. (IPSC) | 22-Jun-21 | Conversion | 11,925,800 | -- | -- | 100% 0 to 11.93M |